April 5th 2025
Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer.
A 67-Year-Old Woman With Ovarian Cancer
April 27th 2021Chirag Shah, MD, MPH, an expert in gynecologic oncology, reviews the case of a 67-year-old woman with ovarian cancer and discusses factors to consider when selecting therapy including the recent results of the PRIMA and NOVA trials of niraparib in patients with ovarian cancer.
Watch
FDA Approves Dostarlimab for Recurrent or Advanced dMMR Endometrial Cancer
April 22nd 2021The FDA has granted accelerated approval to dostarlimab-gxly for the treatment of adult patients with recurrent or advanced endometrial cancer that has progressed on or following prior treatment with platinum-containing chemotherapy and whose cancers have a specific genetic feature known as dMMR, as determined by an FDA approved test.
Read More
Frailty Score, Morphologic Subtype May Indicate Surgical Outcomes in Ovarian Cancer
April 20th 2021In an interview with Targeted Oncology, Katelyn Handley, MD, discussed two studies on ovarian cancer subtypes and the use of a frailty index to determine patient outcomes before, during, and after ovarian cancer debulking surgery.
Read More
FDA Okays Initiation of Endoxifen Study in Ovarian Cancer
April 12th 2021A patient with ovarian cancer has begun treatment with oral endoxifen, an active metabolite of tamoxifen, after a Safe to Proceed Letter was granted by the FDA, according to a press release by Atossa Therapeutics, Inc.
Read More
FDA Has Granted Priority Review to Tisotumab Vedotin for Advanced Cervical Cancer
April 10th 2021The FDA has accepted a biologics license application and granted it a priority review for tisotumab vedotin for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Read More
In women with advanced epithelial ovarian cancer treated in a single-institution study at the Cleveland Clinic, the addition of paclitaxel to cisplatin for hyperthermic intraperitoneal chemotherapy during interval debulking surgery was associated with improved oncologic outcomes compared with cisplatin alone.
Read More
Niraparib Maintains PFS Improvement, But OS Data Are Limited in gBRCA+/- Ovarian Cancer
March 21st 2021Niraparib administered as maintenance therapy showed clinical benefit lasting beyond first progression in patients with platinum-sensitive recurrent ovarian cancer with or without germline BRCA mutations, according to the final results of the ENGOT-OV16/NOVA study.
Read More
Niraparib/Bevacizumab Combo Continues to Show Prolonged PFS in Patients With Advanced Ovarian Cancer
March 20th 2021At the Society of Gynecological Oncology Virtual Annual Meeting on Women’s Cancer data from the phase II OVARIO study continued to show the progression free survival benefit for heavily pretreated patients with advanced ovarian cancer.
Read More
CA-125 surveillance alone could be used to detect disease progression in patients with advanced ovarian cancer and an abnormal CA-125 level at the beginning of frontline maintenance therapy with olaparib (Lynparza) and bevacizumab (Avastin), according to an analysis from the phase 3 PAOLA-1 that was presented at the SGO 2021 Annual Meeting on Women’s Cancer.
Read More
Rucaparib Improves PFS in BRCA+ Relapsed Ovarian Cancer in Confirmatory ARIEL4 Trial
March 20th 2021Compared with standard-of-care chemotherapy, treatment with the PARP inhibitor rucaparib led to a significant prolongation of progression-free survival and improved duration of response in patients with BRCA-mutated advanced, relapsed ovarian cancer, according to primary results from the phase 3 ARIEL4 trial.
Read More
Niraparib Shows Efficacy in Hard-to-Treat Patients With Newly Diagnosed Ovarian Cancer
March 19th 2021Data from a post hoc analysis of the PRIMA/ENGOT-OV26/GOG-3012 phase III trial showed the efficacy of niraparib maintenance therapy for patients with ovarian cancer who had interval debulking surgery or visible residual disease.
Read More
Phase 3 Cemiplimab Trial in Cervical Cancer Stopped Early With Positive OS Results
March 15th 2021A phase 3 trial for cemiplimab monotherapy in comparison with chemotherapy in patients with recurrent or metastatic cervical cancer who previously received chemotherapy treatment is being stopped early due to a unanimous recommendation by the Independent Data Monitoring Committee due to positive overall survival results.
Read More
BLA Submitted to FDA for Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
February 12th 2021A Biologics License Application was submitted to the FDA for tisotumab vedotin as treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
Read More